Cargando…

Enhancement of antibiotic activity by efflux inhibitors against multidrug resistant Mycobacterium tuberculosis clinical isolates from Brazil

Drug resistant tuberculosis continues to increase and new approaches for its treatment are necessary. The identification of M. tuberculosis clinical isolates presenting efflux as part of their resistant phenotype has a major impact in tuberculosis treatment. In this work, we used a checkerboard proc...

Descripción completa

Detalles Bibliográficos
Autores principales: Coelho, Tatiane, Machado, Diana, Couto, Isabel, Maschmann, Raquel, Ramos, Daniela, von Groll, Andrea, Rossetti, Maria L., Silva, Pedro A., Viveiros, Miguel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4412083/
https://www.ncbi.nlm.nih.gov/pubmed/25972842
http://dx.doi.org/10.3389/fmicb.2015.00330
_version_ 1782368601867550720
author Coelho, Tatiane
Machado, Diana
Couto, Isabel
Maschmann, Raquel
Ramos, Daniela
von Groll, Andrea
Rossetti, Maria L.
Silva, Pedro A.
Viveiros, Miguel
author_facet Coelho, Tatiane
Machado, Diana
Couto, Isabel
Maschmann, Raquel
Ramos, Daniela
von Groll, Andrea
Rossetti, Maria L.
Silva, Pedro A.
Viveiros, Miguel
author_sort Coelho, Tatiane
collection PubMed
description Drug resistant tuberculosis continues to increase and new approaches for its treatment are necessary. The identification of M. tuberculosis clinical isolates presenting efflux as part of their resistant phenotype has a major impact in tuberculosis treatment. In this work, we used a checkerboard procedure combined with the tetrazolium microplate-based assay (TEMA) to study single combinations between antituberculosis drugs and efflux inhibitors (EIs) against multidrug resistant M. tuberculosis clinical isolates using the fully susceptible strain H37Rv as reference. Efflux activity was studied on a real-time basis by a fluorometric method that uses ethidium bromide as efflux substrate. Quantification of efflux pump genes mRNA transcriptional levels were performed by RT-qPCR. The fractional inhibitory concentrations (FIC) indicated synergistic activity for the interactions between isoniazid, rifampicin, amikacin, ofloxacin, and ethidium bromide plus the EIs verapamil, thioridazine and chlorpromazine. The FICs ranged from 0.25, indicating a four-fold reduction on the MICs, to 0.015, 64-fold reduction. The detection of active efflux by real-time fluorometry showed that all strains presented intrinsic efflux activity that contributes to the overall resistance which can be inhibited in the presence of the EIs. The quantification of the mRNA levels of the most important efflux pump genes on these strains shows that they are intrinsically predisposed to expel toxic compounds as the exposure to subinhibitory concentrations of antibiotics were not necessary to increase the pump mRNA levels when compared with the non-exposed counterpart. The results obtained in this study confirm that the intrinsic efflux activity contributes to the overall resistance in multidrug resistant clinical isolates of M. tuberculosis and that the inhibition of efflux pumps by the EIs can enhance the clinical effect of antibiotics that are their substrates.
format Online
Article
Text
id pubmed-4412083
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-44120832015-05-13 Enhancement of antibiotic activity by efflux inhibitors against multidrug resistant Mycobacterium tuberculosis clinical isolates from Brazil Coelho, Tatiane Machado, Diana Couto, Isabel Maschmann, Raquel Ramos, Daniela von Groll, Andrea Rossetti, Maria L. Silva, Pedro A. Viveiros, Miguel Front Microbiol Microbiology Drug resistant tuberculosis continues to increase and new approaches for its treatment are necessary. The identification of M. tuberculosis clinical isolates presenting efflux as part of their resistant phenotype has a major impact in tuberculosis treatment. In this work, we used a checkerboard procedure combined with the tetrazolium microplate-based assay (TEMA) to study single combinations between antituberculosis drugs and efflux inhibitors (EIs) against multidrug resistant M. tuberculosis clinical isolates using the fully susceptible strain H37Rv as reference. Efflux activity was studied on a real-time basis by a fluorometric method that uses ethidium bromide as efflux substrate. Quantification of efflux pump genes mRNA transcriptional levels were performed by RT-qPCR. The fractional inhibitory concentrations (FIC) indicated synergistic activity for the interactions between isoniazid, rifampicin, amikacin, ofloxacin, and ethidium bromide plus the EIs verapamil, thioridazine and chlorpromazine. The FICs ranged from 0.25, indicating a four-fold reduction on the MICs, to 0.015, 64-fold reduction. The detection of active efflux by real-time fluorometry showed that all strains presented intrinsic efflux activity that contributes to the overall resistance which can be inhibited in the presence of the EIs. The quantification of the mRNA levels of the most important efflux pump genes on these strains shows that they are intrinsically predisposed to expel toxic compounds as the exposure to subinhibitory concentrations of antibiotics were not necessary to increase the pump mRNA levels when compared with the non-exposed counterpart. The results obtained in this study confirm that the intrinsic efflux activity contributes to the overall resistance in multidrug resistant clinical isolates of M. tuberculosis and that the inhibition of efflux pumps by the EIs can enhance the clinical effect of antibiotics that are their substrates. Frontiers Media S.A. 2015-04-28 /pmc/articles/PMC4412083/ /pubmed/25972842 http://dx.doi.org/10.3389/fmicb.2015.00330 Text en Copyright © 2015 Coelho, Machado, Couto, Maschmann, Ramos, von Groll, Rossetti, Silva and Viveiros. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Microbiology
Coelho, Tatiane
Machado, Diana
Couto, Isabel
Maschmann, Raquel
Ramos, Daniela
von Groll, Andrea
Rossetti, Maria L.
Silva, Pedro A.
Viveiros, Miguel
Enhancement of antibiotic activity by efflux inhibitors against multidrug resistant Mycobacterium tuberculosis clinical isolates from Brazil
title Enhancement of antibiotic activity by efflux inhibitors against multidrug resistant Mycobacterium tuberculosis clinical isolates from Brazil
title_full Enhancement of antibiotic activity by efflux inhibitors against multidrug resistant Mycobacterium tuberculosis clinical isolates from Brazil
title_fullStr Enhancement of antibiotic activity by efflux inhibitors against multidrug resistant Mycobacterium tuberculosis clinical isolates from Brazil
title_full_unstemmed Enhancement of antibiotic activity by efflux inhibitors against multidrug resistant Mycobacterium tuberculosis clinical isolates from Brazil
title_short Enhancement of antibiotic activity by efflux inhibitors against multidrug resistant Mycobacterium tuberculosis clinical isolates from Brazil
title_sort enhancement of antibiotic activity by efflux inhibitors against multidrug resistant mycobacterium tuberculosis clinical isolates from brazil
topic Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4412083/
https://www.ncbi.nlm.nih.gov/pubmed/25972842
http://dx.doi.org/10.3389/fmicb.2015.00330
work_keys_str_mv AT coelhotatiane enhancementofantibioticactivitybyeffluxinhibitorsagainstmultidrugresistantmycobacteriumtuberculosisclinicalisolatesfrombrazil
AT machadodiana enhancementofantibioticactivitybyeffluxinhibitorsagainstmultidrugresistantmycobacteriumtuberculosisclinicalisolatesfrombrazil
AT coutoisabel enhancementofantibioticactivitybyeffluxinhibitorsagainstmultidrugresistantmycobacteriumtuberculosisclinicalisolatesfrombrazil
AT maschmannraquel enhancementofantibioticactivitybyeffluxinhibitorsagainstmultidrugresistantmycobacteriumtuberculosisclinicalisolatesfrombrazil
AT ramosdaniela enhancementofantibioticactivitybyeffluxinhibitorsagainstmultidrugresistantmycobacteriumtuberculosisclinicalisolatesfrombrazil
AT vongrollandrea enhancementofantibioticactivitybyeffluxinhibitorsagainstmultidrugresistantmycobacteriumtuberculosisclinicalisolatesfrombrazil
AT rossettimarial enhancementofantibioticactivitybyeffluxinhibitorsagainstmultidrugresistantmycobacteriumtuberculosisclinicalisolatesfrombrazil
AT silvapedroa enhancementofantibioticactivitybyeffluxinhibitorsagainstmultidrugresistantmycobacteriumtuberculosisclinicalisolatesfrombrazil
AT viveirosmiguel enhancementofantibioticactivitybyeffluxinhibitorsagainstmultidrugresistantmycobacteriumtuberculosisclinicalisolatesfrombrazil